Discuss Vilon on glp1chat
Join the forum to discuss research with other members.
At a glance
Vilon is a two-amino-acid peptide studied for changes in immune-cell activity and gene signals. Experimental work looks at how these cells respond to stress or inflammation rather than at a single established treatment effect.
Immune cells change their activity by switching sets of genes and signaling to neighboring cells. Vilon is explored for whether this very short peptide shifts some of those responses in experimental models. The measured changes help researchers ask how immune regulation works. They are not a direct measure of fewer infections, faster healing or longer life in people.
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The source describes experimental immune and tissue findings. Pulsed research schedules borrowed from related peptides require particular caution when interpreting their relevance.[1][2][3]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Vilon.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 20 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~6.67 mg/mL)
| Phase / Cycle | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Cycle 1, Day 1 | 67 mcg (0.067 mg) | 1 unit (0.01 mL) |
| Cycle 1, Day 2 | 133 mcg (0.133 mg) | 2 units (0.02 mL) |
| Cycle 1, Day 3 | 200 mcg (0.20 mg) | 3 units (0.03 mL) |
| Cycle 1, Day 4 | 267 mcg (0.267 mg) | 4 units (0.04 mL) |
| Cycle 1, Day 5 | 333 mcg (0.33 mg) | 5 units (0.05 mL) |
| Cycle 2+ (Days 1–5) | 333–667 mcg (0.33–0.67 mg) | 5–10 units (0.05–0.10 mL) |
Schedule: Inject once daily subcutaneously for 5 consecutive days, then rest for the remainder of a 4‑week cycle. Repeat monthly[4][5]. For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the pulsed regimen.
- Goal: Support immune modulation and thymic function markers based on preclinical observations[1][2].
- Schedule: 5 consecutive days of subcutaneous injections per 4‑week cycle; repeat for 2–4 cycles.
- Dose Range: 67–667 mcg daily with gradual titration during the first cycle.
- Reconstitution: 3.0 mL per 20 mg vial (~6.67 mg/mL) for accurate low‑volume measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Suggested pulsed titration approach.
- Start: 67 mcg (1 unit) on Day 1; increase by ~67 mcg (1 unit) each day during first cycle.
- Target: 333–667 mcg (5–10 units) daily by Cycle 2 onward.
- Frequency: Once per day (subcutaneous) for 5 consecutive days per cycle[5].
- Cycle Length: 5 days on, ~23 days off (4‑week cycle); run 2–4 cycles.
- Timing: Any consistent time; rotate injection sites.
Read this protocol on Pep Science → · View cited documents ↓
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within ~1 week or aliquot and freeze[10].
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at −20 °C (−4 °F) short‑term or −80 °C (−112 °F) long‑term in dry, dark conditions; minimize moisture exposure[10].
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~1 week or prepare aliquots and freeze to extend stability.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[9].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[7][8].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[9].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[9].
Materials & quantity planning
Source materials checklist · 20 mg
Plan based on an 8–16 week pulsed protocol (5 injection days per 4‑week cycle).
-
Peptide Vials (Vilon, 20 mg each):
- 8 weeks (2 cycles, 10 injections) ≈ 1 vial
- 12 weeks (3 cycles, 15 injections) ≈ 1 vial
- 16 weeks (4 cycles, 20 injections) ≈ 1 vial
-
Insulin Syringes (U‑100, 30‑ or 50‑unit preferred):
- Per cycle: 5 syringes (1/day × 5 days)
- 8 weeks: 10 syringes
- 12 weeks: 15 syringes
- 16 weeks: 20 syringes
-
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8–16 weeks (1 vial): 3 mL → 1 × 10 mL bottle
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per cycle: 10 swabs (2/day × 5 days)
- 8 weeks: 20 swabs
- 12 weeks: 30 swabs
- 16 weeks: 40 swabs → recommend 1 × 100‑count box
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 20 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 03
Research publication
Gavrisheva NA et al. (2005) — Effect of Vilon peptide on TGF‑β1 and vascular permeability in chronic renal failure (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Research publication
Kniaz’kin IA et al. (2002) — Effect of a peptide Vilon on immune aging (Adv Gerontol) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 06
Research publication
Chernyak EY et al. (2000) — Synthetic dipeptide Vilon inhibits tumor growth and prolongs life in mice (Dokl Biol Sci) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 09
Public health resource
MedlinePlus (NIH) — Subcutaneous (SQ) injections: patient information (opens in a new tab)medlineplus.gov
Back to overview ↑ - 10
Source document
Merck KGaA (Millipore Sigma) — Handling and storage guidelines for peptides and proteins (opens in a new tab)www.sigmaaldrich.com
Back to overview ↑ - 11
Public health resource
CDC — Vaccine administration: subcutaneous route (angle/site; no aspiration) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 12
Public health resource
NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.